Table 4 |
||||
|
Sensitivity analysis results. Costs in SEK 2004. |
||||
| Costs avoided |
Net costs |
QALYs |
Cost per QALY |
|
|
|
||||
| Base case |
6,522 134 |
-70,985 |
35 |
<0 |
|
|
||||
| Model parameters |
||||
|
|
||||
| A. Fracture risk [39] |
6,479,356 |
-28,207 |
35 |
<0 |
| A. Fracture risk doubled |
5,978,641 |
472,508 |
33 |
14,327 |
| B. Mortality risk [40] |
7,401,024 |
-949,875 |
29 |
<0 |
| C. Medical treatment costs [21] |
11,793,758 |
-5,342,609 |
35 |
<0 |
| C. Medical treatment costs, average difference |
6,420,258 |
30,891 |
35 |
879 |
| 1 year before and 2 years after hip fracture |
||||
| D. 2nd and following year costs [21] |
6,709,090 |
-257,941 |
35 |
<0 |
| E. Non-market productivity incl. [41] |
6,789,172 |
-338,023 |
35 |
<0 |
| E. Costs in added life-years [14] |
447,200 |
6,003,949 |
35 |
170,907 |
| F. Alternative QoL weights [42] |
6,522,134 |
-70,989 |
48 |
<0 |
| G. Discount rate 0% |
7,535,125 |
-1,083,976 |
45 |
<0 |
| G. Discount rate 5% |
5,986,099 |
465,050 |
30 |
15,313 |
| H. Mortality and hip fracture risks [39,40] |
7,385,325 |
-934,176 |
29 |
<0 |
| I. No costs or QoL effects after 1st year |
1,935,529 |
4,515,620 |
22 |
202,041 |
| J. Another disease; fracture risks doubled, no costs or QoL effects after 1st year |
1,730,899 |
4,720,250 |
21 |
228,805 |
|
|
||||
| Program specific |
||||
|
|
||||
| Program costs +25% |
6,522,134 |
1,541,798 |
35 |
43,888 |
| Program effectiveness: lowest |
2,712,870 |
3,738,279 |
21 |
178,013 |
| Program effectiveness: highest |
12,534,792 |
-6,083,643 |
67 |
<0 |
|
|
||||
|
Johansson et al. Cost Effectiveness and Resource Allocation 2008 6:11 doi:10.1186/1478-7547-6-11 |
||||
